IMGO Imago BioSciences, Inc. Stock Quote

IMGO [NASD]

Index	-	P/E	-	EPS (ttm)	-1.33	Insider Own	1.40%	Shs Outstand	33.71M	Perf Week	-2.37%
Market Cap	443.59M	Forward P/E	-	EPS next Y	-2.54	Insider Trans	-16.30%	Shs Float	32.20M	Perf Month	-21.50%
Income	-42.30M	PEG	-	EPS next Q	-0.48	Inst Own	74.90%	Short Float	6.94%	Perf Quarter	-36.34%
Sales	-	P/S	-	EPS this Y	-116.80%	Inst Trans	-3.22%	Short Ratio	10.87	Perf Half Y	-36.05%
Book/sh	6.37	P/B	2.19	EPS next Y	56.30%	ROA	-20.70%	Target Price	35.75	Perf Year	-
Cash/sh	6.85	P/C	2.04	EPS next 5Y	-	ROE	-46.70%	52W Range	12.85 - 35.68	Perf YTD	-41.04%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-60.82%	Beta	-
Dividend %	-	Quick Ratio	21.90	Sales past 5Y	-	Gross Margin	-	52W Low	8.79%	ATR	1.60
Employees	27	Current Ratio	21.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.11	Volatility	10.80% 10.96%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-142.40%	Profit Margin	-	Rel Volume	0.67	Prev Close	13.66
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 AMC	Payout	-	Avg Volume	205.64K	Price	13.98
Recom	1.20	SMA20	-13.17%	SMA50	-23.26%	SMA200	-34.45%	Volume	136,856	Change	2.34%

Feb-14-22

Initiated

H.C. Wainwright

Buy

$37

May-16-22 08:00AM	Imago BioSciences to Participate in Upcoming Investor Conferences GlobeNewswire +5.59%
May-12-22 04:05PM	Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates GlobeNewswire
08:00AM	Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the 27th Congress of the European Hematology Association (EHA) for 2022 GlobeNewswire
May-09-22 08:00AM	Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer GlobeNewswire -5.88%
May-03-22 08:00AM	Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia GlobeNewswire -5.01%
Apr-14-22 06:15AM	Are Institutions Heavily Invested In Imago BioSciences, Inc.'s (NASDAQ:IMGO) Shares? Simply Wall St.
Mar-24-22 04:05PM	Imago BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
Mar-23-22 04:05PM	Imago BioSciences Appoints Michael Arenberg to Chief Operating and Business Officer GlobeNewswire
Feb-28-22 04:05PM	Imago BioSciences to Participate in the Cowen 42nd Annual Health Care Conference GlobeNewswire
09:00AM	Why Earnings Season Could Be Great for Imago BioSciences (IMGO) Zacks
Feb-04-22 04:05PM	Imago BioSciences to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference GlobeNewswire
Jan-19-22 08:00AM	PepGen Appoints Laurie Keating as Chair of Board of Directors GlobeNewswire
Jan-14-22 06:28AM	Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth Simply Wall St. -7.37%
Dec-17-21 08:00AM	Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies PR Newswire +12.13%
Dec-12-21 09:46AM	Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021 Business Wire
Dec-11-21 12:01PM	Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021 Business Wire
Dec-01-21 08:00AM	Imago BioSciences to Host Virtual Investor Event GlobeNewswire
Nov-18-21 04:05PM	Imago BioSciences Appoints Laurie Keating to Board of Directors Business Wire
Nov-11-21 04:05PM	Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference GlobeNewswire +9.35%
Nov-10-21 04:05PM	Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates GlobeNewswire
Nov-04-21 04:05PM	Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition Business Wire
Oct-16-21 10:45AM	What Is The Ownership Structure Like For Imago BioSciences, Inc. (NASDAQ:IMGO)? Simply Wall St.
Sep-20-21 08:00AM	Imago BioSciences Announces Its Addition to the Russell 2000® Index Business Wire -15.16%
Aug-19-21 04:01PM	Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates Business Wire
Jul-30-21 08:02AM	Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia Business Wire +8.40%
Jul-26-21 04:15PM	Imago BioSciences, Inc. Announces Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Jul-20-21 05:15PM	Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering Business Wire
Jul-15-21 10:34PM	Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock Business Wire

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Eichorn Laura G.	See Remarks	Feb 22	Option Exercise	2.52	8,000	20,160	215,737	Feb 24 06:05 PM
Eichorn Laura G.	See Remarks	Feb 22	Sale	21.60	8,000	172,813	207,737	Feb 24 06:05 PM
Peppe Jennifer	See Remarks	Feb 11	Option Exercise	2.10	7,000	14,700	155,809	Feb 15 04:26 PM
Eichorn Laura G.	See Remarks	Feb 11	Option Exercise	1.52	4,000	6,080	211,737	Feb 15 04:25 PM
Tapper Amy E.	See Remarks	Feb 11	Option Exercise	1.52	3,000	4,560	122,047	Feb 15 04:24 PM
Eichorn Laura G.	See Remarks	Feb 11	Sale	23.61	4,000	94,455	207,737	Feb 15 04:25 PM
Peppe Jennifer	See Remarks	Feb 11	Sale	23.76	7,000	166,295	148,809	Feb 15 04:26 PM
Tapper Amy E.	See Remarks	Feb 11	Sale	23.78	3,000	71,347	119,047	Feb 15 04:24 PM
Peppe Jennifer	See Remarks	Feb 09	Option Exercise	1.86	10,000	18,574	158,809	Feb 11 04:23 PM
Eichorn Laura G.	See Remarks	Feb 09	Option Exercise	1.52	4,000	6,080	211,737	Feb 11 04:22 PM
Tapper Amy E.	See Remarks	Feb 09	Option Exercise	1.52	3,000	4,560	122,047	Feb 11 04:21 PM
Tapper Amy E.	See Remarks	Feb 09	Sale	21.54	3,000	64,614	119,047	Feb 11 04:21 PM
Eichorn Laura G.	See Remarks	Feb 09	Sale	21.56	4,000	86,254	207,737	Feb 11 04:22 PM
Peppe Jennifer	See Remarks	Feb 09	Sale	22.26	10,000	222,581	148,809	Feb 11 04:23 PM
Peppe Jennifer	See Remarks	Feb 07	Option Exercise	1.98	13,000	25,760	161,809	Feb 09 04:06 PM
Peppe Jennifer	See Remarks	Feb 07	Sale	20.48	13,000	266,202	148,809	Feb 09 04:06 PM
Tapper Amy E.	See Remarks	Feb 01	Option Exercise	2.10	6,500	13,650	125,547	Feb 03 04:13 PM
Tapper Amy E.	See Remarks	Feb 01	Sale	19.76	6,500	128,412	119,047	Feb 03 04:13 PM
Peppe Jennifer	See Remarks	Jan 12	Option Exercise	1.79	14,000	25,059	162,809	Jan 14 06:48 PM
Tapper Amy E.	See Remarks	Jan 12	Option Exercise	1.52	6,000	9,120	125,047	Jan 14 06:47 PM
Eichorn Laura G.	See Remarks	Jan 12	Option Exercise	1.52	8,000	12,160	215,737	Jan 14 06:46 PM
Tapper Amy E.	See Remarks	Jan 12	Sale	19.96	6,000	119,750	119,047	Jan 14 06:47 PM
Peppe Jennifer	See Remarks	Jan 12	Sale	19.95	14,000	279,353	148,809	Jan 14 06:48 PM
Eichorn Laura G.	See Remarks	Jan 12	Sale	19.96	8,000	159,651	207,737	Jan 14 06:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience